{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"IL-31 Mechanism of Action and Clinical Implications for Prurigo Nodularis","description":"This is the second episode of a two-part miniseries, &quot;IL-31 Inhibition for Treatment of Prurigo Nodularis&quot; series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, &quot;IL-31 Mechanism and Clinical Implications for PN&quot;, featuring Dr. Shawn Kwatra, discusses the following topics:   Mechanism of action for IL-31 inhibitor nemolizumab   Clinical safety and efficacy data for nemolizumab for treatment of PN   Strategies for prescribing IL-31 inhibitors in clinical practice   Pearls for patient selection and addressing treatment challenges   ","author_name":"DermDocs","author_url":"http:\/\/dermdocs.libsyn.com\/website","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/34145255\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/181575950"}